183 related articles for article (PubMed ID: 34957746)
41. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis.
Schultz MJ
J Antimicrob Chemother; 2004 Jul; 54(1):21-8. PubMed ID: 15190022
[TBL] [Abstract][Full Text] [Related]
42. Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin.
Djamin RS; Talman S; Schrauwen EJA; von Wintersdorff CJH; Wolffs PF; Savelkoul PHM; Uzun S; Kerstens R; van der Eerden MM; Kluytmans JAJW
Antimicrob Resist Infect Control; 2020 Jul; 9(1):116. PubMed ID: 32723393
[TBL] [Abstract][Full Text] [Related]
43. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy.
Altenburg J; de Graaff CS; van der Werf TS; Boersma WG
Respiration; 2011; 81(1):75-87. PubMed ID: 20733282
[TBL] [Abstract][Full Text] [Related]
44. [Long-term macrolide treatment in adult chronic bronchial diseases: benefits and limits].
Jouneau S; Desrues B
Presse Med; 2014 May; 43(5):510-9. PubMed ID: 24631048
[TBL] [Abstract][Full Text] [Related]
45. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
Ni Chroinin M; Greenstone IR; Danish A; Magdolinos H; Masse V; Zhang X; Ducharme FM
Cochrane Database Syst Rev; 2005 Oct; (4):CD005535. PubMed ID: 16235410
[TBL] [Abstract][Full Text] [Related]
46. The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases.
Eraković Haber V; Bosnar M; Kragol G
Future Med Chem; 2014 Apr; 6(6):657-74. PubMed ID: 24895894
[TBL] [Abstract][Full Text] [Related]
47. Effects of azithromycin on bronchial remodeling in the natural model of severe neutrophilic asthma in horses.
Mainguy-Seers S; Boivin R; Pourali Dogaheh S; Beaudry F; Hélie P; Bonilla AG; Martin JG; Lavoie JP
Sci Rep; 2022 Jan; 12(1):446. PubMed ID: 35013387
[TBL] [Abstract][Full Text] [Related]
48. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T
Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887
[TBL] [Abstract][Full Text] [Related]
49. Anti-inflammatory effects of macrolides in lung disease.
Jaffé A; Bush A
Pediatr Pulmonol; 2001 Jun; 31(6):464-73. PubMed ID: 11389580
[TBL] [Abstract][Full Text] [Related]
50. Macrolides in cystic fibrosis.
McArdle JR; Talwalkar JS
Clin Chest Med; 2007 Jun; 28(2):347-60. PubMed ID: 17467553
[TBL] [Abstract][Full Text] [Related]
51. Use of macrolides in lung diseases: recent literature controversies.
Silva Filho LV; Pinto LA; Stein RT
J Pediatr (Rio J); 2015; 91(6 Suppl 1):S52-60. PubMed ID: 26354869
[TBL] [Abstract][Full Text] [Related]
52. [Antibiotic therapy in asthma exacerbation and in cystic fibrosis in children].
Breborowicz A
Pol Merkur Lekarski; 2011 May; 30(179):349-51. PubMed ID: 21675140
[TBL] [Abstract][Full Text] [Related]
53. Use of long-term macrolide therapy in chronic obstructive pulmonary disease.
Ramos FL; Criner GJ
Curr Opin Pulm Med; 2014 Mar; 20(2):153-8. PubMed ID: 24378875
[TBL] [Abstract][Full Text] [Related]
54. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?
Holimon TD; Chafin CC; Self TH
Drugs; 2001; 61(3):391-418. PubMed ID: 11293649
[TBL] [Abstract][Full Text] [Related]
55. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
56. Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease.
Mammen MJ; Sethi S
Pol Arch Med Wewn; 2012; 122(1-2):54-9. PubMed ID: 22353707
[TBL] [Abstract][Full Text] [Related]
57. Pharmacotherapy for lower respiratory tract infections.
Liapikou A; Torres A
Expert Opin Pharmacother; 2014 Nov; 15(16):2307-18. PubMed ID: 25216725
[TBL] [Abstract][Full Text] [Related]
58. Low-dose, long-term macrolide therapy in asthma: An overview.
Hatipoglu U; Rubinstein I
Clin Mol Allergy; 2004 Mar; 2(1):4. PubMed ID: 15023231
[TBL] [Abstract][Full Text] [Related]
59. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy.
Blasi F; Bonardi D; Aliberti S; Tarsia P; Confalonieri M; Amir O; Carone M; Di Marco F; Centanni S; Guffanti E
Pulm Pharmacol Ther; 2010 Jun; 23(3):200-7. PubMed ID: 20025989
[TBL] [Abstract][Full Text] [Related]
60. Macrolides in cystic fibrosis.
Bell SC; Senini SL; McCormack JG
Chron Respir Dis; 2005; 2(2):85-98. PubMed ID: 16279156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
